louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02468544: Development and Feasibility Testing of a Mobile Phone-Based HIV Primary Care Engagement Intervention
Official title: Development and Feasibility Testing of a Mobile Phone-Based HIV Primary Care Engagement Intervention
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: HIV
Adherence
Keywords: Engagement in care
mHealth
Lead sponsor: Columbia University
Sponsor class: OTHER
First posted: 2015-06-11
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is an open-trial pilot study in which adult methadone maintenance treatment patients who are living with HIV but are not engaged in HIV primary care (i.e., missed appointments, non-adherence to medication) will be recruited to participate in a HIV primary care engagement study. The purpose of this study is to develop and test the feasibility and acceptability of a mobile phone-based health (mHealth) text messaging intervention to improve engagement in HIV primary care among substance abusing populations with HIV.


Eligibility criteria: Inclusion Criteria:

* Client of a methadone maintenance treatment program
* HIV positive (status confirmed by medical records)
* At least 18 years of age
* English speaking
* Comfortable using a mobile phone (to send and receive text messages)
* Lives in New York City
* Willingness to attend at least two design sessions
* Willingness to attend one usability testing session, and participate in a post-usability survey and exit interview.

Primary outcomes:
measure: Acceptability of Intervention
timeFrame: 30 days
measure: Feasibility of Intervention
timeFrame: 30 days
Secondary outcomes:
measure: Efficacy of the intervention
timeFrame: 30 days
Other outcomes:
measure: Self-efficacy to self-manage HIV infection
timeFrame: 30 days
measure: Improvements in HIV knowledge
timeFrame: 30 days
Locations:
city: New York
country: United States
facility: Acacia Network/Promesa
state: New York
Study officials:
affiliation: Columbia University
name: Jemima A. Frimpong, PhD., MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04924244: Effect of Music on Pain and Anxiety in Chronic Pain Patients Undergoing Lumbar Interventional Procedures.
Official title: Effect of Music on Pain and Anxiety in Chronic Pain Patients Undergoing Lumbar Interventional Procedures
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Chronic Pain
Anxiety
Lead sponsor: Milton S. Hershey Medical Center
Sponsor class: OTHER
First posted: 2021-06-11
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate, subjectively and objectively, whether playing music during procedures for treatment of chronic lower back pain has an effect on patients' anxiety and pain. The investigators hypothesize that playing music will result in reduced patient reported anxiety and pain scores and less variation from baseline of vital signs versus patients in the control group without music therapy. This is a pilot study.


Eligibility criteria: Inclusion Criteria:

1. Age greater than or equal to 18
2. Female or male
3. Patients undergoing standard of care lumbar spinal interventional procedures including: epidural steroid injections, facet injections, medial branch blocks

Exclusion Criteria:

1. Patients who cannot consent for themselves, including cognitively impaired patients.
2. Non-English speaking patients
3. Patients taking beta blocker medication
4. Patients that have a pacer and have a set rate
5. Patients with self-reported hearing problems or with hearing aids

Primary outcomes:
measure: Pre-procedure State-Trait Anxiety Inventory (STAI) Score
timeFrame: Within 30 minutes prior to the subject's interventional procedure
measure: Post-procedure State-Trait Anxiety Inventory (STAI) Score
timeFrame: Within 30 minutes following to the subject's interventional procedure
Secondary outcomes:
measure: Pre-procedural Visual Analog Score (VAS) for pain
timeFrame: Within 30 minutes prior to the subject's interventional procedure
measure: Post procedural Visual Analog Score (VAS)
timeFrame: Within 30 minutes following the subject's interventional procedure
Other outcomes:
Locations:
city: Hershey
country: United States
facility: Milton S. Hershey Medical Center
state: Pennsylvania
Study officials:
affiliation: Milton S. Hershey Medical Center
name: Bunty Shah
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06922344: Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor
Official title: Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Pityriasis Versicolor
Keywords: Pityriasis Versicolor
Fluconazole
Itraconazole
Lead sponsor: Khyber Teaching Hospital
Sponsor class: OTHER
First posted: 2025-04-10
Enrollment: 106
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study compares the efficacy of two drugs, namely flucanazole and itraconazole for the treatment of a common fungal infection of skin.

Detailed description: Pityriasis versicolor is a common fungal infection of the superficial skin layers. Avalible treatment options include topical and systemic drugs. fluconazole and itraconazole are commonly used systemic agents. The aim of this study is to compare the efficacy of the two systemic drugs.

Eligibility criteria: Inclusion Criteria:

* All cases of Pityriasis versicolor

Exclusion Criteria:

* Patients with history of chronic renal or liver disease, malignancy , or undergoing any kind of chemotherapy or radiotherapy or having cardiac conduction abnormalities.
* Patients who received any anti-fungal therapy in the last one month.
* Pregnant or lactating women.

Primary outcomes:
measure: Efficacy of Treatment
timeFrame: Upto 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Peshawar
country: Pakistan
facility: Khyber Teaching Hospital
state: KPK
Study officials:
References:
Clinical trial NCT05068544: Adolescent Normative Sport Movement Analysis
Official title: Adolescent Normative Sport Movement Analysis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lower Extremity Problem
Musculoskeletal Injury
Lead sponsor: MultiCare Health System Research Institute
Sponsor class: OTHER
First posted: 2021-10-06
Enrollment: 40
Sex: ALL
Minimum age (years): 13
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A group of 40 neurotypical and healthy adolescent subjects who participate in organized "land-based" sports will be recruited for this data collection. Adolescent subjects will be ages 13-25 with an equal number of male and female (gender assigned at birth).

Brief summary: The objective of this study is to collect baseline data from a normative population of adolescents who participate in organized "land-based" sports, that gender and age matches some of the population of patients expected to be treated at Mary Bridge Children's Therapy Services, MultiCare affiliated therapy centers, and Mary Bridge Specialty Clinics who will be seen in the Research and Movement Lab. This project will recruit 40 patients between the ages of 13-25 years old. Non-invasive measurements of movement patterns will be collected during common sport-related activities over a single data collection session.


Eligibility criteria: Inclusion Criteria:

* Age between 13-25 years.
* Participate in a "land-based" organized sport in the last 1 year with intent on continued participation in the next year.
* Perform sport-related activities such as running/sprinting, cutting maneuvers, and jumping.
* Tolerate adhesive markers placed on skin and clothing.
* Willing and interested in participating.

Exclusion Criteria:

* Neuromuscular disorders such as cerebral palsy, muscular dystrophy, myotonic dystrophy, spinal muscular atrophy, peripheral neuropathy, or other generalized muscle and/or nerve issues.
* Currently undergoing treatment or receiving medication that affects movement.
* Requires ankle/knee bracing to safely perform running, sprinting, jumping activities.
* History of orthopedic surgery to lower limbs.
* In last 6 months: receiving/seeking medical treatment for injury.
* Difficulty performing sport-related activities.
* Pain that has inhibited participation in sports/daily activities in the last 3 months.

Primary outcomes:
measure: Observation-based movement analyses
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Puyallup
country: United States
facility: Mary Bridge Children's Therapy Unit
state: Washington
Study officials:
References:
Clinical trial NCT01177644: Safety and Preliminary Efficacy Study of PDS-1.0 in Patients With Neovascular AMD
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Age-Related Macular Degeneration
Lead sponsor: Forsight Vision4
Sponsor class: INDUSTRY
First posted: 2010-08-09
Enrollment: 0
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will evaluate the safety and preliminary effectiveness of PDS 1.0 in patients with neovascular AMD.


Eligibility criteria: Key Inclusion Criteria:

* Diagnosis of CNV secondary to AMD confirmed by fluorescein angiography, not previously treated
* Retinal thickness due to edema of at least 300um in the study eye
* Best corrected visual acuity of 20/80 or worse in the study eye
* Best corrected visual acuity of 20/40 or better in the fellow eye

Exclusion Criteria:

* Evidence of scarring CNV (e.g. geographic atrophy) in the study eye
* Fibrosis \>75% of lesion area in the study eye

Primary outcomes:
measure: Change in retinal thickness measured by Optical Coherence Tomography
timeFrame: Monthly
Secondary outcomes:
measure: Change in Best Corrected Visual Acuity
timeFrame: Monthly
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
Study officials:
References:
Clinical trial NCT04887844: Efficacy of Corticosteroid and Local Anesthetic Injections Patients With Concomitant Pes Anserine Bursitis
Official title: Comparison of the Efficacy of Corticosteroid and Local Anesthetic Injections Combined With Conventional Physiotherapy in Patients With Concomitant Pes Anserine Bursitis and Knee Osteoarthritis:
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteoarthritis Knees Both
Keywords: Pain
Knee
Rehabilitation
Lead sponsor: Abant Izzet Baysal University
Sponsor class: OTHER
First posted: 2021-05-14
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Group I was received physiotherapy+lidocaine injection, Group II was received physiotherapy+betamethasone dipropionate injection, and group III was only received conventional physiotherapy.
Primary purpose: TREATMENT

Brief summary: To evaluate the efficiencies of local corticosteroid injections and local anesthetics in patients with concomitant pes anserine bursitis and osteoarthritis.

Detailed description: Several treatment options have been tried with varying success rates, including nonsteroidal anti-inflammatory drugs, physiotherapy modalities, cold application with ice-packs, and injection of local anesthetics and/or corticosteroids. Despite a relatively high frequency of this painful condition, surprisingly, few studies have evaluated treatment strategies in randomized controlled study design. To the best of our knowledge, no study in the literature made a comparison of the efficacy of local anesthetic and corticosteroid injections in addition to physiotherapy in the treatment of pes anserine bursitis yet. Thus, we aimed to compare the treatment efficacies of physiotherapy alone, physiotherapy + local anesthetic injection, and physiotherapy + local corticosteroid injection in a randomized controlled study design in patients with concomitant osteoarthritis and pes anserine bursitis.

Eligibility criteria: Inclusion Criteria:

* Patients having stage II-IV knee osteoarthritis along with pes anserine bursitis
* Symptom onset for more than three months

Exclusion Criteria:

* Patients who underwent knee operations
* had an inflammatory rheumatic disease
* had a history of knee trauma
* had a meniscus tear
* valgus/varus deformity
* received injection treatment to pes anserine bursa during the preceding year

Primary outcomes:
measure: Visual analogue scale
timeFrame: eight weeks
Secondary outcomes:
measure: Western Ontario and McMaster Universities Osteoarthritis Index
timeFrame: eight weeks
measure: 3-meter walk test
timeFrame: eight weeks
Other outcomes:
Locations:
city: Bolu
country: Turkey
facility: Abant Izzet Baysal University
state: Merkez
Study officials:
affiliation: Bolu Abant Izzet Baylsa University
name: Mustafa Fatih Yaşar, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Bolu Abant Izzet Baylsa University
name: Ramazan KURUL, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00119444: Evaluation of Acetabular Perfusion After Ganz Osteotomy by Positron Emission Tomography
Official title: Evaluation of Acetabular Perfusion After Ganz Osteotomy by Positron Emission Tomography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteoarthritis
Keywords: PET
Periacetabular osteotomy
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2005-07-13
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine the blood flow in acetabulum after periacetabular osteotomy by Positron Emission Tomography (PET).

Detailed description: As a consequence of periacetabular osteotomy the blood flow in acetabulum is decreased. After periacetabular osteotomy has been performed there is fine contact between the osteotomised acetabulum and the rest of the pelvis and the potential for healing is good. However, it has not been investigated how much the blood flow in acetabulum is changed after surgery. The blood flow is considered to be vital for how the pelvis heals after surgery. Most likely, the blood flow is important in relation to which degree osteoarthritis can be prevented after periacetabular osteotomy.

It is possible to estimate the blood flow by Positron Emission Tomography of the dysplastic hip joint pre- and postoperatively. In this study the blood flow and fluoride uptake is quantified by Positron emission tomography based on measurements of O-15 water and F-18 fluoride.

Eligibility criteria: Inclusion Criteria:

* Patients with radiologically diagnosed hip dysplasia (CE-angle \< 25°).
* Patients with osteoarthritis graded 0, 1 or 2 defined according to Tönnis' classification. Patients with pain from hip
* Age \> 18 years.
* Minimum 110° flexion in hip joint and closed growth zones in the pelvic.
* Informed consent.

Exclusion Criteria:

* Patients with neurological diseases
* Patients with calvé-Legg-Perthes syndrome.
* Patients where an femoral intertrochanteric osteotomy is necessary.
* Patients with medical sequelae after earlier hip surgery.
* Females who are pregnant.
* Patients with metal implants.

Primary outcomes:
measure: changes in blood flow
timeFrame: within the first three weeks after operation
Secondary outcomes:
measure: fluoride uptake
timeFrame: within the first three weeks after operation
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Orthopaedic Center, Aarhus University Hospital
Study officials:
affiliation: Orthopaedic Center, Aarhus University Hospital, Aarhus, Denmark
name: Kjeld Søballe, MD, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05613244: Descriptive Study of a Cohort of Orbital Solitary Fibrous Tumors
Official title: Orbital Solitary Fibrous Tumors: Description of a Case Series and Study of the Recurrence Rate
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Orbital Tumor
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2022-11-14
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with an orbital solitary fibrous tumor

Brief summary: Orbital solitary fibrous tumors are rare tumors with an intermediate potential of malignancy. Orbital solitary fibrous tumors' prognostic criteria are still poorly understood.

Some patients with orbital solitary fibrous tumors have been treated at the Adolphe de Rothschild Foundation Hospital. This cohort will be studied to describe the recurrence rate and to identify predictive factors of recurrence or metastasis.


Eligibility criteria: Inclusion Criteria:

* Patients treated at the Adolphe de Rothschild foundation hospital for an orbital solitary fibrous tumor between 01/01/2014 and 09/30/2020

Exclusion Criteria:

* Opposition of the patient (or of the relative if the patient is deceased)
* Patients benefiting from a legal protection measure
* Pregnant or breastfeeding woman

Primary outcomes:
measure: Population characteristics
timeFrame: inclusion
measure: Medical history
timeFrame: inclusion
measure: Radiological lesion features
timeFrame: inclusion
measure: Pathological lesion characteristics
timeFrame: inclusion
measure: Intraoperative data
timeFrame: inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital Fondation A. de Rothschild
Study officials:
affiliation: Hôpital Fondation A. de Rothschild
name: Natasha MAMBOUR
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04347044: The Effect of Pulmonary Rehabilitation on Bronchoscopic Volume Reduction Process Success
Official title: The Effect of Pulmonary Rehabilitation on Bronchoscopic Volume Reduction Process Success
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Emphysema
Pulmonary Rehabilitation
Bronchoscopic Lung Volume Reduction
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2020-04-15
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The data of patients undergoing bronchoscopic volume reduction procedure will be analyzed retrospectively. Patients will be divided into two groups as patients with and without Pulmonary Rehabilitation before the procedure, and changes in functional levels of patients will be compared.

Detailed description: The data of patients who underwent bronchoscopic volume reduction between January 2013 and March 2019 will be examined.

Patients will be divided into two groups as pulmonary rehabilitation applied (PR group) and not applied (Control group) before the procedure.

Changes in the parameters of initial and rehabilitation follow-up will be examined.

Eligibility criteria: Inclusion Criteria:

* Between the ages of 18-75
* Patients with a diagnosis of emphysema and bronchoscopic procedures

Exclusion Criteria:

• Patients who develop complications related to the procedure after bronchoscopic procedure.

Primary outcomes:
measure: Six minute walking test
timeFrame: 20 minutes
measure: Pulmonary Function Tests
timeFrame: 15 minutes
Secondary outcomes:
measure: Carbonmonoxide diffusion test
timeFrame: 15 minutes
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05223244: Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed IC
Official title: Bladder Capacity as an Objective Measure of Response to Intravesical Treatment of Newly Diagnosed Interstitial Cystitis: a Prospective, Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Interstitial Cystitis
Painful Bladder Syndrome
Keywords: dimethyl sulfoxide (DMSO)
Intravesical instillations
bupivacaine, triamcinolone, and heparin (BTH)
Bladder instillations
Lead sponsor: Endeavor Health
Sponsor class: OTHER
First posted: 2022-02-03
Enrollment: 83
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: At each of the six weekly treatment visits, bladder capacity was determined, followed by the intravesical treatment of either DMSO or BTH.
Primary purpose: TREATMENT

Brief summary: A comparative study of subjective outcomes following intravesical treatment of interstitial cystitis (IC) is lacking in the literature. Furthermore, an objective measure to determine the efficacy of intravesical treatment for interstitial cystitis has yet to be defined. Change in bladder capacity following therapy has been investigated; however, a formal statistical analysis of its utility in determining efficacy has yet to be performed. The primary objective of this prospective, randomized study is to determine whether there is a significant difference in subjective improvement in IC symptoms in women with newly diagnosed IC when treated with either dimethyl sulfoxide (DMSO) or bupivacaine, triamcinolone, and heparin (BTH) instillations. The secondary objective is to determine whether change in bladder capacity can be used as an objective measure of response to intravesical therapy for newly diagnosed interstitial cystitis. Our long-term goals are to improve the scientific understanding of therapy for interstitial cystitis, to improve patient counseling prior to initiation of treatment, and to better identify patients likely to receive inadequate relief of symptoms following intravesical treatment so that an alternative treatment can be pursued.


Eligibility criteria: Inclusion Criteria:

* newly diagnosed interstitial cystitis/painful bladder syndrome

Exclusion Criteria:

* History of pelvic radiation, a history of bladder cancer, or a history of bladder resection

Primary outcomes:
measure: Reduction of at least 29.5% in ICSI score
timeFrame: 6 weeks
Secondary outcomes:
measure: Bladder capacity
timeFrame: 6 weeks
Other outcomes:
Locations:
Study officials:
References: